MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. - Wikidata - awgldk - TriplyDB

MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer.

MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer.

http://www.wikidata.org/entity/Q35747341

about

Epigenetic Regulation of Epidermal Stem Cell Biomarkers and Their Role in Wound Healing RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action microRNA regulation of Wnt signaling pathways in development and disease The crosstalk between microRNAs and the Wnt/β-catenin signaling pathway in cancer Reference miRNAs for miRNAome analysis of urothelial carcinomas.MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer.MicroRNAs in apoptosis, autophagy and necroptosis The evolving understanding of microRNA in bladder cancer MiR-3162-3p Is a Novel MicroRNA That Exacerbates Asthma by Regulating β-Catenin.SENP2 regulates MMP13 expression in a bladder cancer cell line through SUMOylation of TBL1/TBLR1.Bladder cancer: a simple model becomes complex.MicroRNA-1 down-regulates proliferation and migration of breast cancer stem cells by inhibiting the Wnt/β-catenin pathway.The role of the VEGF-C/VEGFRs axis in tumor progression and therapy.miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer.Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells.The non-canonical role of vascular endothelial growth factor-C axis in cancer progression microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer.MEK1 signaling promotes self-renewal and tumorigenicity of liver cancer stem cells via maintaining SIRT1 protein stabilization CCL5 promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-507 in human chondrosarcoma cells.β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met MicroRNA-224 inhibits proliferation and migration of breast cancer cells by down-regulating Fizzled 5 expression.Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues.MicroRNAs as therapeutic targets and their potential applications in cancer therapy.Oncogenic Wnt/β-catenin signalling pathways in the cancer-resistant epididymis have implications for cancer research.miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells.Aberrant expression of microRNAs in bladder cancer.microRNAs in cancer cell response to ionizing radiation.miRNA panels as biomarkers for bladder cancer.Regulation of breast cancer stem cell features.miR-613 inhibits bladder cancer proliferation and migration through targeting SphK1.Noncoding RNAs Regulating Cancer Signaling Network.miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.Copy number variants associated with 18p11.32, DCC and the promoter 1B region of APC in colorectal polyposis patients MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in human bladder cancer.microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.MicroRNA-3619-5p suppresses bladder carcinoma progression by directly targeting β-catenin and CDK2 and activating p21

P2860

Q26771827-4EE6E63C-3AC2-472E-941E-9E00870DCDDB Q26773479-7A095F3A-6C48-4D78-9365-816208A6F07A Q27011654-179288BE-C7A5-463F-AAA9-0F8562CF237E Q28076568-4FF285A4-122F-4F99-82B9-F32B85BBEFC2 Q34321313-4EBCF294-102A-48E2-B951-6DAB8DF30336 Q35113163-6A2EDC97-A970-4C45-9071-49582161377B Q35832148-BB12B61A-3394-4A71-85C0-7E38D534D8B8 Q35852484-8D7A157C-108F-47E4-8E2A-67069C023C76 Q35951046-75DA6AEF-73E6-41D8-BA0B-26775906130D Q36060614-32E3B416-6FC6-4B1C-AD4E-51A38AB46951 Q36108115-F09EFB9D-6A7E-4369-9DD7-8C41611F0690 Q36561545-F200C242-BAB5-44D0-8732-B3ACE25F8822 Q36589860-FDCC3DB1-8CB2-4C66-BD84-124EB6558C9D Q36905274-35D24978-9CE5-48E5-B1F9-710E3294798B Q37040086-49E7D0BA-33A9-4E78-B13D-C6E60FE10269 Q37071029-E2225732-52C0-4F5E-964F-0557B1C85C70 Q37151392-8AEF3BAC-2904-49CF-8B60-DCFDCC81E49B Q37190384-12C16552-492F-45A1-AFEF-BB8FFA4E9DF3 Q37392868-75F8EA2B-1790-4BEC-BF2C-60CD4B6B3243 Q37417188-5FC1B150-3897-48E8-9030-0A183ADAE608 Q37462436-FA77D174-55B7-440C-A57F-BCE22666D442 Q37580183-D4A8268F-C904-4683-91B4-3FFDBF5878D7 Q37636708-52879AD0-A9F6-45E9-B1AC-E14F7D4E1534 Q38018097-B496DDA4-2134-4BEE-8858-C0CD8FCAE22B Q38060099-F0B0D8FD-6837-4EB3-8ACA-0ECDEA2FC5D1 Q38096240-B38D12A4-39A8-4BD5-896F-F8F9A27AF0AA Q38109811-A10CDA65-FA5E-4BC7-A3C9-5ECEDDDFBA25 Q38160950-6526557F-9599-4872-AE00-9626D79F3B92 Q38239829-89885F31-70EA-459D-ABB3-5C2FA5E5038E Q38359738-10AFED4C-E791-467D-BAB8-5AFC6F924CCD Q38848862-81A6AD15-DCFF-4F4B-AA1C-5C668192A7E0 Q38885498-F4570E7B-ABBD-438B-9384-FDC0C8A86E1A Q39156112-CD1B789F-2E59-492F-A4CD-286952AB0EB7 Q39432577-BAD36943-B2CD-4E88-A2E8-1132E11414E6 Q39973575-FF6E0E98-94DA-4B95-9D46-ABFC6315B4D9 Q40741536-F6CAE941-3960-47AD-899E-9897B3CDA650 Q53059683-95B8CF6D-14F2-4D4F-BA7D-F36FCBDC4D55 Q58712586-74989369-7F41-45BD-AE69-7354BC72AD54

P2860

MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer.

http://www.wikidata.org/entity/Q35747341

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

MicroRNA-1826 targets VEGFC, b ...... P2K1) in human bladder cancer.

@ast

MicroRNA-1826 targets VEGFC, b ...... P2K1) in human bladder cancer.

@en

type

label

MicroRNA-1826 targets VEGFC, b ...... P2K1) in human bladder cancer.

@ast

MicroRNA-1826 targets VEGFC, b ...... P2K1) in human bladder cancer.

@en

prefLabel

MicroRNA-1826 targets VEGFC, b ...... P2K1) in human bladder cancer.

@ast

MicroRNA-1826 targets VEGFC, b ...... P2K1) in human bladder cancer.

@en

P1433

Q35747341-76013B15-1B47-4390-AAB2-C8D4667B9707

P1476

Q35747341-C581A8EF-403F-402A-9F8E-760AA2D3227B

P2093

Q35747341-2B7E382E-E533-4931-A6C5-D055B82961A2

Q35747341-3F16DE5B-2AD5-4275-8E72-125F9E601A5D

Q35747341-4426D710-2F00-4B88-8041-FDE78A8D1459

Q35747341-5834B8A3-F224-4068-B5C0-880FA12DE1D0

Q35747341-914A3098-C1C2-4DD4-9B8D-5B732E029706

Q35747341-B8ABE821-E2A1-42A6-B783-BEAB06B2983B

P2860

Q35747341-07DB6BCA-F119-4A30-8039-9A2272B9B7CD

Q35747341-0AAEF764-1DB6-46B3-BC47-1AA0EEE0CB0A

Q35747341-1CBBB405-6E8D-4E20-B95F-D7DE37E32536

Q35747341-23CE0B18-642A-436A-9AE2-CE5A28D3644F

Q35747341-2A3E3C62-5A1A-4877-9737-683741C43001

Q35747341-2BB4D5B9-661C-4D66-8145-87EEB15EE446

Q35747341-3B2B3793-8CBA-48D5-B50D-824B894740EF

Q35747341-3C4946CF-9392-44CC-82AF-EA5D0BDCEDD9

Q35747341-3ECED6F1-4A4D-4D8A-BAFD-C1CAAF33BC45

Q35747341-44CE56E4-9A50-481E-B51C-EC722197FF3F

P304

Q35747341-B04F8E39-69A2-499A-A233-CE9712D42E57

P31

Q35747341-16462107-9CC6-4441-8537-16572A890057

P356

Q35747341-2D972FDB-8F41-41EB-BD89-0E3C7AE75A60

P407

Q35747341-9A16E60D-CBE1-44D6-80B6-DEB0DA039940

P433

Q35747341-5B6B3AE4-A031-4E24-B754-215F416ED4F7

P478

Q35747341-E6EE3084-569A-4E6C-B34F-2147D307237C

P577

Q35747341-EAC50993-9074-478C-97AF-F9D14E4D8492

P5875

Q35747341-1E212C87-2C4B-4FE2-A5F0-7DA87DA38E6C

P698

Q35747341-AC71F454-CFB2-440C-8EAA-D873B6F5184D

P921

Q35747341-5DBC85E2-2812-4373-8D64-7F2D5CBB194E

P932

Q35747341-6D415FF1-E874-4378-BE1E-A0F54AA29B75

P356

P1433

P1476

MicroRNA-1826 targets VEGFC, b ...... P2K1) in human bladder cancer.

@en

P2093

Hiroshi Hirata

http://www.w3.org/2001/XMLSchema#string

Koji Ueno

http://www.w3.org/2001/XMLSchema#string

Rajvir Dahiya

http://www.w3.org/2001/XMLSchema#string

Varahram Shahryari

http://www.w3.org/2001/XMLSchema#string

Yuji Hinoda

http://www.w3.org/2001/XMLSchema#string

Z Laura Tabatabai

http://www.w3.org/2001/XMLSchema#string

P2860

Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy

Targeting RAS signalling pathways in cancer therapy

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade

miRDB: a microRNA target prediction and functional annotation database with a wiki interface

WNT and beta-catenin signalling: diseases and therapies

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)

Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis

miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors.

MicroRNAs as potential cancer therapeutics.

P304

41-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CARCIN/BGR239

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51766496

http://www.w3.org/2001/XMLSchema#string

P698

22049531

http://www.w3.org/2001/XMLSchema#string

P921

P932

3276333

http://www.w3.org/2001/XMLSchema#string